Opinion

Video

Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Author(s):

Joseph Mikhael, MD

Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.

Video content above is prompted by the following question:

  • Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.
  • Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?
  • What can we look forward to through the end of the year and beyond?
Related Videos
Sabarish Ayyappan, MD
Sabarish Ayyappan, MD
Related Content
Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com
February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Kyle Munz
Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.
cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com
February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

Kyle Munz
The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.
Kirollos Hanna, PharmD
January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD
Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers
January 22nd 2025

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

Luke Halpern Laura Joszt, MA
Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com
January 21st 2025

High Infection Risk in MM: Insights From the Preimmunotherapy Era

Kyle Munz
Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.
MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

Kyle Munz
This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo